Eton Pharmaceuticals, Inc.
ETON
$58.83
-$0.52-0.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 407.36% | 67.82% | -20.35% | -21.91% | 38.27% |
| Total Depreciation and Amortization | 71.37% | 116.21% | 252.88% | 203.05% | 157.63% |
| Total Amortization of Deferred Charges | -54.95% | -62.26% | -37.24% | 3,219.15% | 2,058.46% |
| Total Other Non-Cash Items | 29.66% | 103.86% | 201.65% | 193.08% | 142.05% |
| Change in Net Operating Assets | -389.57% | 15.29% | 21.03% | 324.23% | 86.45% |
| Cash from Operations | 23.69% | 186.32% | 986.07% | 904.71% | 29,033.33% |
| Capital Expenditure | -3,258.33% | -3,300.00% | -1,180.77% | -2,014.29% | 14.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -84.73% | -84.73% | -- | -207.23% | -207.23% |
| Cash from Investing | 59.61% | 59.59% | 99.17% | -1,345.84% | -1,335.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -679.22% | -- | -- | 100.00% | 75.00% |
| Issuance of Common Stock | -45.32% | -79.49% | -90.34% | 3,142.32% | 2,959.01% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -94.84% | -94.58% | -97.50% | 2,768.19% | 2,771.52% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -80.92% | 192.94% | 270.58% | 1,032.01% | 298.48% |